The USPSTF Recommendation Statement on Coronary Heart Disease Risk Assessment
Authors: Robert J. Glynn
Journal: Annals of Internal Medicine (2010)

Letters16 March 2010The USPSTF Recommendation Statement on Coronary Heart Disease Risk AssessmentRobert J. Glynn, PhD, ScDRobert J. Glynn, PhD, ScDFrom Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-6-201003160-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The statement from the U.S. Preventive Services Task Force (USPSTF) (1) that “persons with low (<10%) Framingham risk scores do not benefit from aggressive risk factor modification” and the conclusion that high-sensitivity C-reactive protein (CRP) does not improve a physician's ability to guide treatment do not reflect current randomized trial data. The USPSTF conclusions should be of particular concern for women, almost all of whom have Framingham risk scores less than 10%.JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) (2) studied apparently healthy men and women with high-sensitivity CRP ...References1. U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:474-82. [PMID: 19805770] LinkGoogle Scholar2. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. [PMID: 18997196] CrossrefMedlineGoogle Scholar3. Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al; JUPITER Study Group. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes. 2009;2:616-23. [PMID: 20031900] MedlineGoogle Scholar4. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult–2009 recommendations. Can J Cardiol. 2009;25:567-79. [PMID: 19812802] CrossrefMedlineGoogle Scholar5. Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer CM, et al; NACB LMPG Committee Members. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem. 2009;55:378-84. [PMID: 19106185] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115.Disclosures: Dr. Glynn has received research support from AstraZeneca. The Brigham & Women's Hospital holds patents that relate to the use of inflammatory biomarkers in cardiovascular disease. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUsing Nontraditional Risk Factors in Coronary Heart Disease Risk Assessment: U.S. Preventive Services Task Force Recommendation StatementThe USPSTF Recommendation Statement on Coronary Heart Disease Risk Assessment Matthew J. Budoff The USPSTF Recommendation Statement on Coronary Heart Disease Risk Assessment Michael J. Blaha , Catherine Y. Campbell , and Aaron Horne The USPSTF Recommendation Statement on Coronary Heart Disease Risk Assessment Eric L. Matteson , Cynthia S. Crowson , and Sherine E. Gabriel The USPSTF Recommendation Statement on Coronary Heart Disease Risk Assessment Ned Calonge and Diana Pettiti Metrics 16 March 2010Volume 152, Issue 6Page: 403KeywordsC-reactive proteinsCardiovascular diseasesMyocardial infarctionRisk managementStatinsTreatment guidelinesVascular surgery ePublished: 16 March 2010 Issue Published: 16 March 2010 CopyrightCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...